AP News / EIN Presswire · Feb 2026
Abalone Bio and Mount Sinai announced peer-reviewed preclinical data on first publicly reported functional characterization of CB2 activating antibody agonists, AB120 and AB150.
We create activating antibodies to treat diseases others can’t.
Company research
Public company, workplace, funding, and market signals
Overview
Abalone Bio is a private biotechnology company using engineered biology and machine learning to discover and design target-activating antibodies for hard-to-drug membrane proteins, especially GPCRs.
Primary product
FAST (Functional Antibody Selection Technology) platform for discovering and designing activating antibody therapeutics
Founded
2017
Headquarters
Emeryville, California, United States
Team size
11-50
Industry
Biotechnology Research
Sub-industry
Antibody drug discovery / therapeutic biotechnology
Offices
Emeryville, California, United States
Open Positions
0 jobs at Abalone Bio
No open positions
Check back later for new openings